A phase III study of cetuximab (CET) plus either brivanib alaninate (BRIV) versus placebo in patients with chemotherapy-refractory KRAS wild-type (WT) advanced colorectal cancer (aCRC): The NCIC CTG/AGITG CO.20 trial.

被引：4
|
作者：
Shapiro, J. D.
Siu, L. L.
Zalcberg, J. R.
Moore, M. J.
Ringash, J.
Mittmann, N.
Simes, J.
O'Callaghan, C. J.
Tu, D.
Walters, I. B.
Magoski, N.
Smith, P.
Nomikos, D.
Zhu, L.
Savoie, M.
Virk, S.
El-Tahche, F.
Gill, R.
Price, T. J.
Jonker, D. J.
机构：
[1] Cabrini Hosp, Malvern, Australia
[2] Princess Margaret Hosp, Toronto, ON M4X 1K9, Canada
[3] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia
[4] Princess Margaret Hosp, Dept Med Oncol, Toronto, ON M4X 1K9, Canada
[5] Univ Toronto, Toronto, ON, Canada
[6] Sunnybrook Hlth Sci Ctr, HOPE Res Ctr, Toronto, ON M4N 3M5, Canada
[7] ANZGOG, Camperdown, NSW, Australia
[8] NCIC Clin Trials Grp, Kingston, ON, Canada
[9] Bristol Myers Squibb Co, Wallingford, CT 06492 USA
[10] Univ Sydney, NHMRC Clin Trials Ctr, Camperdown, NSW, Australia
[11] Queen Elizabeth Hosp, Woodville, SA 5011, Australia
[12] Ottawa Hosp, Ottawa, ON, Canada
[13] Univ Ottawa, Ottawa, ON, Canada
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 15期
关键词：
D O I：
10.1200/jco.2011.29.15_suppl.tps163
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS163
引用
收藏
页数：1
相关论文
共 27 条
  • [21] A prospective Phase II study to examine the relationship between quality of life and adverse events of first-line chemotherapy plus cetuximab in patients with KRAS wild-type unresectable metastatic colorectal cancer: QUACK trial
    Iwamoto, Shigeyoshi
    Ooki, Akira
    Morita, Satoshi
    Hara, Hiroki
    Tanioka, Hiroaki
    Satake, Hironaga
    Kataoka, Masato
    Kotaka, Masahito
    Kagawa, Yoshinori
    Nakamura, Masato
    Shingai, Tatsushi
    Ishikawa, Masashi
    Miyake, Yasuhiro
    Sudo, Takeshi
    Hashiguchi, Yojiro
    Yabuno, Taichi
    Sakamoto, Junichi
    Tsuji, Akihito
    Ando, Masahiko
    Yamaguchi, Kensei
    CANCER MEDICINE, 2018, 7 (09): : 4217 - 4227
  • [22] EXPERT study: Randomized phase III trial of radical surgery and postoperative mFOLFOX6 versus perioperative mFOLFOX6 plus cetuximab in patients with KRAS wild-type resectable colorectal liver metastases (CLMs).
    Mise, Yoshihiro
    Hasegawa, Kiyoshi
    Oba, Masaru
    Yamaguchi, Kensei
    Uetake, Hiroyuki
    Yoshino, Takayuki
    Morita, Satoshi
    Takahashi, Keiichi
    Unno, Michiaki
    Shimada, Yasuhiro
    Muro, Kei
    Yoshida, Kazuhiro
    Mori, Masaki
    Baba, Hideo
    Shimada, Mitsuo
    Saiura, Akio
    Matsumura, Masaru
    Ishigure, Kiyoshi
    Sugihara, Kenichi
    Kokudo, Norihiro
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)
  • [23] Mutations within the EGFR signaling pathway: Influence on efficacy in FIRE-3-A randomized phase III study of FOLFIRI plus cetuximab or bevacizumab as first-line treatment for wild-type (WT) KRAS (exon 2) metastatic colorectal cancer (mCRC) patients
    Stintzing, Sebastian
    Jung, Andreas
    Rossius, Lisa
    Modest, Dominik Paul
    von Weikersthal, Ludwig Fischer
    Decker, Thomas
    Kiani, Alexander
    Al-Batran, Salah-Eddin
    Vehling-Kaiser, Ursula
    Heintges, Tobias
    Moehler, Markus
    Scheithauer, Werner
    Kirchner, Thomas
    Heinemann, Volker
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (03)
  • [24] Influence of adjuvant pretreatment on outcome of FIRE-3 (AIO KRK-0306): A randomized phase III study of FOLFIRI plus cetuximab or bevacizumab as first-line treatment for wild-type (WT) KRAS (exon 2) metastatic colorectal cancer (mCRC) patients
    Stintzing, Sebastian
    Modest, Dominik Paul
    von Weikersthal, Ludwig Fischer
    Decker, Thomas
    Kiani, Alexander
    Vehling-Kaiser, Ursula
    Al-Batran, Salah-Eddin
    Heintges, Tobias
    Lerchenmuller, Christian A.
    Kahl, Christoph
    Seipelt, Gernot
    Kullmann, Frank
    Stauch, Martina
    Scheithauer, Werner
    Held, Swantje
    Giessen, Clemens Albrecht
    Moehler, Markus Hermann
    Jung, Andreas
    Kirchner, Thomas
    Heinemann, Volker
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
  • [25] Randomized phase II study of panitumumab (Pmab) plus irinotecan (CPT-11) versus cetuximab (Cmab) plus CPT-11 in patients with KRAS wild-type (WT) metastatic colorectal cancer (mCRC) following treatment with fluoropyrimidine, CPT-11, and oxaliplatin (L-OHP) chemotherapy: WJOG6510G
    Sakai, Daisuke
    Taniguchi, Hiroya
    Tamura, Takao
    Sugimoto, Naotoshi
    Esaki, Taito
    Okuda, Hiroyuki
    Matsumoto, Toshihiko
    Yamazaki, Kentaro
    Denda, Tadamichi
    Yamaguchi, Kensei
    Tsuda, Takashi
    Hosokawa, Ayumu
    Makiyama, Akilaka
    Toblmatsu, Kazutoshi
    Goda, Fuminori
    Otsu, Satoshi
    Kishimoto, Junil
    Boku, Narikazu
    Nakamura, Shinichiro
    Hyodo, Ichinosuke
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [26] A blinded placebo (P)-controlled phase I/II dose-escalation study (DES) of brivanib (B), an oral selective dual inhibitor of FGF and VEGF signaling, in combination with cetuximab (C) and irinotecan (I) in patients (pts) with KRAS wild-type (KWT) advanced or metastatic colorectal cancer (annCRC): Safety tolerability, and pharmacokinetics (PK) findings.
    Park, Y.
    El-Khoueiry, A. B.
    Gracian, A. C.
    Pfeifer, P.
    Chacon, M.
    Amadori, D.
    Fokstuen, T.
    Chemidlin, J.
    Kollia, G.
    Nuyten, D. S.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [27] Randomized phase II study of panitumumab (Pmab) plus irinotecan (CPT-11) versus cetuximab (Cmab) + CPT-11 in patients (pts) with KRAS wild-type (WT) metastatic colorectal cancer (mCRC) after fluoropyrimidine (FU), CPT-11, and oxaliplatin (L-OHP) failure: WJOG6510G
    Sugimoto, Naotoshi
    Sakai, Daisuke
    Tamura, Takao
    Hara, Hiroki
    Nishina, Tomohiro
    Esaki, Taito
    Okuda, Hiroyuki
    Denda, Tadamichi
    Tsuda, Masahiro
    Satoh, Taroh
    Makiyama, Akitaka
    Yamazaki, Kentaro
    Kuramochi, Hidekazu
    Hosokawa, Ayumu
    Tsuda, Takashi
    Taniguchi, Hiroya
    Kishimoto, Junji
    Boku, Narikazu
    Hyodo, Ichinosuke
    Muro, Kei
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)
123